Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes

Leukemia

Volumn 14, Issue 12, 2000, Pages 2085-2094

  Solary, E ^a,b   Mannone, L ^a   Moreau, D ^a   Caillot, D ^a   Casasnovas, R O ^a   Guy, H ^a   Grandjean, M ^a   Wolf, J E ^a   Andre F ^a   Fenaux, P ^c   Canal, P ^d   Chauffert, B ^a,b   Wotawa, A ^b   Bayssas, M ^e   Genne, P ^f  

^a HÔPITAL DU BOCAGE   (France)

^b INSERM   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e DEBIOPHARM SA   (Switzerland)

^f Oncodesign SA   (France)

Author keywords

Cinchonine; Drug resistance; Lymphomas; Myelomas; P glycoprotein; Phase I clinical trial

Indexed keywords

CINCHONINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; METHYLPREDNISOLONE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FEVER; HEADACHE; HEART DISEASE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TINNITUS; TORSADE DES POINTES; VERTIGO; VOMITING; XEROSTOMIA;

EID: 17744390861     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401945     Document Type: Article

References (62)

1. Clinical relevance of drug resistance genes in malignant diseases
2. P-glycoprotein and multi-drug resistance
3. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
4. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
5. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
6. Cortisol is transported by the multidrug resistance gene P-glycoprotien
7. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas
8. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
9. Multidrug resistance in lymphomas
10. The role of MDR-1 in refractory lymphoma
11. Drug resistance in multiple myeloma
12. MDR1 gene expression in chronic lymphocytic leukemia
13. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD
14. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
15. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
16. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
17. Pharmacology of drugs that alter multidrug resistance in cancer
18. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations
19. Potential usefulness of quinine for the circumvention of the anthracycline resistance in clinical practice
20. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM
21. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia
22. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomised multicentric study
23. Quinine improves the results of intensive chemotherapy in myelodysplatic syndromes expressing P-glycoprotein: Results of a randomized study
24. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vitro and in vivo
25. Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM
26. Cinchonine per os: Efficient circumvention of P-glycoprotein-mediated multidrug resistance
27. Studies on the chemotherapy of human malaria. III. The physiological disposition and antimalarial activity of cinchona alkaloids
28. Comparative disposition kinetics of two diastereoisomeric pairs of cinchona alkaloids in the dog
29. An analysis of time-relations of electrocardiograms
30. Effects of verapamil on chronic doxorubicin-induced cardiotoxicity in dogs
31. Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A
32. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
33. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance
34. Treatment of refractory and relased acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar)
35. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
36. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo
37. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial
38. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration
39. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy
40. The effect of dextro-, levo- and racemic verapamil on atrioventricular conduction in humans
41. How to measure the QT interval: What is normal?
42. Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective
43. QTc prolongation measured by standard 12-lead ECG is an independent risk factor for sudden death due to cardiac arrest
44. Torsades de pointes: Electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities
45. Quinidine syncope: Torsades de pointes with low quinidine plasma concentrations
46. Ventricular arrhytmia and torsade de pointes: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial
47. Partial synthesis of 6′hydroxycinchonine and its antiarrhythmic activity in mice
48. The antiarrhythmic activities of 6′hydroxycinchonine and 6′allyloxycinchonine compared with quinidine in mice
49. Beta-blocking effect of propafenone based on spectral analysis of heart variability
50. Neural activity and ventricular fibrillation
51. Measurement of parasympathetic activity from 24-hour ambulatory elctrocardiograms and its reproductibility and sensitivity in normal subjects, patients with symptomatic myocardial ischemia, and patients with diabetes mellitus
52. Role of sympathetic nervous system in non-ischemic ventricular arrhythmias
53. Torsades de pointes: Definition and management
54. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
55. Cyclosporine A as a modifier agent in salvage treatment of acute leukemia (AL)
56. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study
57. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer
58. Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma
59. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel
60. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression
61. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter
62. P-glycoprotein, a marker of cancer-cell behavior